NiKem Research Srl Enters Into Research Service Agreement with InterMune, Inc.

26-Jun-2007

NiKem Research Srl, an Italian drug discovery service provider, announced that it has entered into a Research Service Agreement with InterMune, Inc. Under the terms of the agreement, NiKem will, in the next 12 months, use its medicinal chemistry and early ADMET/PK platform and expertise to design, synthesize and profile drug-like compounds aimed towards specific, undisclosed pulmonology targets of interest for InterMune. Financial terms of the agreement were not disclosed.

According to the company, by pursuing this business opportunity with InterMune, NiKem Research further diversifies its client portfolio in Europe, the United States and Australia, now comprising large pharmaceutical corporations, small biotechs and a number of medium-sized companies.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances